SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Zhang Yuanyuan)
 

Sökning: WFRF:(Zhang Yuanyuan) > DDR1/2 enhance KIT ...

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

Liu, Anbu (författare)
Ningxia Medical University
Zhang, Shaoting (författare)
Ningxia Medical University
Wang, Ming (författare)
Ningxia Medical University
visa fler...
Zhang, Liangying (författare)
Ningxia Medical University
Xu, Shidong (författare)
Tongren Hospital Shanghai Jiao Tong University School Of Medicine
Nasimian, Ahmad (författare)
Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments
Li, Shujing (författare)
Ningxia Medical University
Zhao, Sien (författare)
Ningxia Medical University
Cao, Xu (författare)
Ningxia Medical University
Tian, Jinhai (författare)
Ningxia Medical University
Yu, Yuanyuan (författare)
Ningxia Medical University
Fan, Zhaoyang (författare)
Ningxia Medical University
Xiao, Kun (författare)
Ningxia Medical University
Zhao, Hui (författare)
Chinese University of Hong Kong
Kazi, Julhash U. (författare)
Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments
Ma, Lijun (författare)
Tongren Hospital Shanghai Jiao Tong University School Of Medicine
Sun, Jianmin (författare)
Ningxia Medical University
visa färre...
 (creator_code:org_t)
2024
2024
Engelska 19 s.
Ingår i: Molecular Carcinogenesis. - 0899-1987. ; 63:1, s. 75-93
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Gastrointestinal stromal tumors (GISTs) are predominantly initiated by KIT mutations. In this study, we observed that discoidin domain receptors 1 and 2 (DDR1 and DDR2) exhibited high expression in GISTs, were associated with KIT, and enhanced the activation of both wild-type KIT and primary KIT mutants. Inhibition of DDR1/2 led to a reduction in the activation of KIT and its downstream signaling molecules, ultimately impairing GIST cell survival and proliferation in vitro. Consequently, treatment of mice carrying germline KIT/V558A mutation with DDR1/2 inhibitor significantly impeded tumor growth, and the combined use of DDR1/2 inhibitor and imatinib, the first-line targeted therapeutic agent for GISTs, markedly enhanced tumor growth suppression. In addition, DDR1/2 inhibition resulted in decreased KIT expression, while KIT inhibition led to upregulation of DDR1/2 expression in GISTs. The presence of DDR1/2 also decreased the sensitivity of wild-type KIT or primary KIT mutants to imatinib, indicating a possible role for DDR1/2 in promoting GIST survival during KIT-targeted therapy. The development of drug-resistant secondary KIT mutations is a primary factor contributing to GIST recurrence following targeted therapy. Similar to primary KIT mutants, DDR1/2 can associate with and enhance the activation of secondary KIT mutants, further diminishing their sensitivity to imatinib. In summary, our data demonstrate that DDR1/2 contribute to KIT activation in GISTs and strengthen resistance to imatinib for both primary and secondary KIT mutants, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

DDR
GIST
imatinib
KIT
mutation

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy